From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs) ; volume:56 ; number:2 ; year:2017 ; pages:462-488 ; extent:27
Angewandte Chemie / International edition. International edition ; 56, Heft 2 (2017), 462-488 (gesamt 27)
- Urheber
-
Mantaj, Julia
Jackson, Paul J. M.
Rahman, Khondaker M.
Thurston, David E.
- DOI
-
10.1002/anie.201510610
- URN
-
urn:nbn:de:101:1-2022091608512283490346
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mantaj, Julia
- Jackson, Paul J. M.
- Rahman, Khondaker M.
- Thurston, David E.
Ähnliche Objekte (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology